67-30-1
中文名稱
四碘甲狀腺乙酸
英文名稱
3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID
CAS
67-30-1
分子式
C14H8I4O4
分子量
747.83
MOL 文件
67-30-1.mol
更新日期
2024/12/11 13:13:55
67-30-1 結構式
基本信息
中文別名
四碘甲狀腺乙酸左甲狀腺素EP雜質D
左旋甲狀腺素EP雜質D
3,3',5,5'-四碘甲腺-乙酸
英文別名
TETRACtetraiodothyroaceticacid
Levothyroxine EP Impurity D
3,3’,5,5’-tetraiodo-thyroaceticaci
3,5,3',5'-Tetraiodothyroacetic acid
3,3',5,5'-TETRAIODOTHYRO-ACETIC ACID
acide3,5,3’,5’-tetraiodothyroacetique
3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)benzeneaceticacid
3,5-diiodo-4-(4-hydroxy-3,5-diiodophenoxy)-benzeneaceticaci
3,5-DIIODO-4-(4-HYDROXY-3,5-DIIODOPHENOXY)PHENYLACETIC ACID
所屬類別
分析化學：藥典標準品和雜質標準品物理化學性質
熔點219-220 °C (decomp)
沸點544.8±50.0 °C(Predicted)
密度2.727±0.06 g/cm3(Predicted)
儲存條件−20°C
溶解度丙酮：可溶 19.60 - 20.40mg/mL，透明，無色（或淡黃色至黃色）
酸度系數(shù)(pKa)3.98±0.10(Predicted)
形態(tài)粉末晶體
顏色白色到黃色到綠色
InChIKeyPPJYSSNKSXAVDB-UHFFFAOYSA-N
常見問題列表
生物活性
Tetrac (Tetraiodothyroacetic acid)，L-甲狀腺素 (T4) 的天然衍生物，是甲狀腺素整合素受體拮抗劑。Tetrac 阻斷 T4 和 3,5,3'-triiodo-L-thyronine (T3) 在整聯(lián)蛋白 αvβ3 上甲狀腺激素的細胞表面受體處的作用。Tetra 具有抗血管生成和抗腫瘤活性。體外研究
Tetrac (0.01-1 μM; 2-6 d) induces anti-proliferation in HT-29 and HCT116 cells with different
K-RAS
status.
Tetrac (0.1 μM; 30 min) inhibits activation of ERK1/2 in HT-29 and HCT116 cells.
Tetrac (0.1 μM; 24 h) inhibits expression of
CCND1
and
c-Myc
, but promotes expression of
CASP2
and
THBS1
.
Cell Proliferation Assay
| Cell Line: | HT-29 and HCT116 cells |
| Concentration: | 0.01, 0.1, 1 μM |
| Incubation Time: | 0, 2, 4, 6 days |
| Result: | Induced anti-proliferation of K-RAS wild-type colorectal cancer cells. |
Western Blot Analysis
| Cell Line: | HT-29 and HCT116 cells |
| Concentration: | 0.1 μM |
| Incubation Time: | 30 min |
| Result: | Inhibited constitutively activated ERK1/2, and this inhibition can remove by anti-integrin αvβ3 antibody pretreatment. |
體內研究
Tetrac (35 μg; p.o. for 40 days) inhibits tumor inoculation, growth and integrin expression in mice.
| Animal Model: | Wild-type male Balb/C mice aged 8 weeks are inoculated with 102B16F10 or B16LS9 cells |
| Dosage: | 35 μg per day |
| Administration: | P.o. (added to the drinking water) daily for 40 days |
| Result: |
Delayed the onset of ocular melanoma.
Reduced the S-100 and integrin staining level in the B16F10 mice model. |